- Home
- DOUG vs NYXH Comparison
DOUG vs NYXH Comparison
Compare DOUG & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | NYXH |
|---|---|---|
| Founded | 1911 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Building operators | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.1M | 188.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DOUG | NYXH |
|---|---|---|
| Price | $2.67 | $4.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | ★ 292.1K | 52.7K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,030,928,000.00 | $6,616,215.00 |
| Revenue This Year | $17.61 | $79.25 |
| Revenue Next Year | N/A | $297.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.67 | ★ 10.96 |
| 52 Week Low | $1.48 | $4.35 |
| 52 Week High | $3.20 | $11.87 |
Technical Indicators
Market Signals| Indicator | DOUG | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 48.97 |
| Support Level | $2.66 | $4.69 |
| Resistance Level | $2.90 | $5.04 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 59.62 | 74.58 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.